key: cord-0975934-80kxgqrd authors: Korompoki, Eleni; Gavriatopoulou, Maria; Fotiou, Despina; Ntanasis‐Stathopoulos, Ioannis; Dimopoulos, Meletios A.; Terpos, Evangelos title: Late‐onset hematological complications post COVID‐19: An emerging medical problem for the hematologist date: 2021-11-08 journal: Am J Hematol DOI: 10.1002/ajh.26384 sha: 95707de41989221620310a0b341ef3b286736ab0 doc_id: 975934 cord_uid: 80kxgqrd Coronavirus disease 19 (COVID‐19) is considered a multisystemic disease. Several studies have reported persistent symptoms or late‐onset complications after acute COVID‐19, including post‐COVID‐19 hematological disorders. COVID‐19‐induced coagulopathy, an immunothrombotic state, has been linked to thromboembolic and hemorrhagic events. Late‐onset thrombocytopenia related to immune system dysregulation has also been reported as a rare manifestation post COVID‐19. Close monitoring of laboratory dynamics is considered essential to identify timely abnormal values that need further investigation, providing supportive care whenever indicated. The role of hematologists is essential in terms of the multidisciplinary approach of long COVID‐19. This review summarizes all the available evidence on post‐acute COVID‐19 hematological complications. Coronavirus disease pandemic had spread rapidly with devastating consequences worldwide. The mortality rate ranges from 3% to 5%, while approximately 80% of patients hospitalized with COVID-19 and 60% of those admitted to intensive care units (ICUs) survive. 1 Older people and those with comorbidities are at increased risk of death and complications from COVID-19. 2,3 COVID-19 survivors might experience multiple organ impairment with a significant impact on their quality of life post recovery. [4] [5] [6] Although it is well known that the disease primarily manifests as a respiratory tract infection, several studies have demonstrated that it should be considered a multisystemic disease including cardiovascular impairment, respiratory illness, gastrointestinal disorders, neurological symptoms, as well as hematopoietic and immune system dysregulation. [6] [7] [8] [9] The multisystemic aspects of acute COVID-19 have been thoroughly evaluated; however, the long-term complications are still an underexplored area. "Long (haul)-covid" is used to describe the ongoing effects of COVID-19 infection, which possibly encompasses different entities; post-intensive care syndrome, post-viral fatigue syndrome, and longterm COVID-19 syndrome. 10 During COVID-19 pandemic, micro and macrovascular thrombotic complications have emerged as common clinical complications of the disease, particularly among critically ill and hospitalized patients. 11, 12 The risk of pulmonary microvascular thrombosis and arterial thrombotic events (infarction, stroke, limb ischemia) is also increased, albeit to a lesser extent than venous thrombosis (up to 17% in a recent meta-analysis). [13] [14] [15] [16] [17] Here we comprehensively review the long-term hematological complications that have been described post COVID-19 recovery, providing guidance for their prevention and management. A comprehensive literature search was performed in PubMed using both controlled vocabulary and free text terms for COVID-19 and late/long-term hematologic complications. Updates were performed at regular intervals throughout the review process until September 1, 2021. The search strategy was as follows: ("Hematologic" OR "Hematologic Disease" OR "Blood Disease" OR "Blood Diseases" OR "Blood Hematological Diseases") AND ("COVID-19" OR COVID19 OR "COVID 2019" OR "novel coronavirus" OR "SARS-CoV" or "SARS-CoV-2" OR "SARS2" or "2019-nCoV" OR ncov19 OR ncov-19 OR "2019-novel CoV" OR sarscov2 OR sarscov-2 OR Sars-coronavirus2 OR Sars-coronavirus-2 OR SARS-like coronavirus* OR coronavirus-19) AND (complication* OR damag* OR delayed OR after or post* OR survivor* OR following OR secondary OR chronic OR late* OR "new onset" OR long* OR permanent* OR sequence OR persist* OR "follow up" OR "follow-up"). Articles were initially screened based on title and abstract. Relevant articles were assessed by full-text reading. All types of studies (case reports, case series, retrospective and prospective studies, and clinical trials) were considered. Two independent reviewers (E.K. and D.F.) screened the literature. All relevant papers reporting on hematological complications related to long COVID-19 were included. Studies reporting only complications during the acute phase of the disease were excluded. Available evidence is summarized and discussed. 3 | POST-ACUTE COVID-19 HEMATOLOGICAL COMPLICATIONS COVID-19-induced coagulopathy (CIC) is an immunothrombotic state that appears to be more prothrombotic than hemorrhagic (Table 1) . 25 The optimal thromboprophylactic practice across the spectrum of the disease has not been established yet, but multiple ongoing randomized controlled trials (RCTs) are addressing this question (Table 2) . 26 Individual institutions and professional societies have published interim recommendations to guide anticoagulation strategies. [27] [28] [29] With regard to pathophysiology, SARS-CoV-2 invades vascular endothelial cells directly and induces a suitable environment for the migration and aggregation of immune cells via negative regulation of the ACE-2 receptor activity and angiotensin II accumulation. 30, 31 Proinflammatory and procoagulant cytokine release and endothelial injury lead to the subsequent activation of the coagulation cascade, impaired fibrinolysis and thrombin generation, and modification of the hemostatic environment. [31] [32] [33] [34] Heparin has demonstrated significant effects in reducing the procoagulant environment and the relevant vascular inflammation. 30 The hyperinflammatory response induces endothelitis, 30,35 but it is not clear how long endothelitis can persist in the convalescent phase of the disease. It has been postulated that low-grade endothelial activation and subsequent downstream signaling of prothrombotic pathways and low-level inflammation may persist after the acute phase of the disease. 36 The risk of thrombotic complications in the post-acute COVID-19 phase is probably linked to the duration and severity of a hyperinflammatory state, although how long this persists is unknown. B cells may also play a role in long COVID-19 autoimmunity. Antiphospholipid antibodies were detected in 52% of patients (24% anti-phosphatidylserine/ prothrombin IgG, 18%, anti-phosphatidylserine/prothrombin IgG, and 23% anti-cardiolipin IgM) in one hospitalized cohort, and there was an association with increased neutrophil activity and more severe outcomes. 37, 38 It is hypothesized that endothelial cell (EC) pathway activation may contribute in long COVID-19 pathogenesis (Figure 1 ). In a recent study, 50 patients were evaluated in a median of 68 days post COVID-19. EC activation, thrombin generation, and NETosis compounds were assessed. Thrombin generation assays demonstrated shorter lag times in combination with increased endogenous thrombin potential and peak thrombin. EC biomarkers such as VWF:Ag, VWF propeptide (VWFpp), and Factor VIII (FVIII:C) were significantly increased as measured in the convalescent COVID-19 plasma. Plasma-soluble thrombomodulin (sTM) levels were also significantly elevated. Patients with advanced age or suffering from comorbidities, or those who required hospitalization, revealed sustained endotheliopathy. These findings strongly indicate that the presence of endotheliopathy might be involved in the underlying pathogenesis of long COVID-19. 39 A recent study showed that SARS-CoV-2 can cause potential breakdown of the hematopoietic stem cells differentiation, leading to acute anemia of inflammation, thrombocytopenia, and thrombosis ( Figure 1 ). The Sars-CoV-2 RNA enters ex vivo the primary CD34+ HSCs, inducing the formation of defective megakaryocytic and erythroid cells. Viral particles from affected CD34+ HSCs confer the greatest risk for severe thrombosis related to Sars-CoV-2 infection. 40 Epidemiological data examining the risk of thrombosis post hospital discharge are limited, but the overall the risk is similar to that of patients hospitalized with acute medical illnesses other than COVID-19. Based on data from studies with variability in outcome ascertainment, the rate of venous thromboembolism (VTE) in the post-acute phase of COVID-19 disease is well below 5% (Table 1) . 41 In a single-center retrospective report of 163 patients who did not receive thromboprophylaxis post discharge, the cumulative incidence of thrombosis (segmental pulmonary embolism, intracardiac thrombus, ischemic stroke, VTE) at 30 days was 2.5%, for VTE alone 0.6% (median time to event 23 days), and for hemorrhage 3.7%. 18 Similar rates are reported in other small retrospective studies. 19 One prospective study assessed 146 patients (28% received thromboprophylaxis) at 6 weeks post discharge; one asymptomatic deep vein thrombosis (DVT) (0.7%) and one symptomatic pulmonary embolism (0.7%) were diagnosed. No bleedings were reported. At 6 weeks, 32% of ward patients and 42% of ICU patients had elevated D-dimer levels. 20 In another outpatient cohort study of 175 patients, at 60 days the incidence of arterial events was 0% and venous events 0.71% (1 PE at 9 days post discharge), and no bleedings were reported. 21 Similar rates were also reported from a Chinese study of post-acute COVID-19 . 22 In another study, the VTE rate was 1.6% 23 among 4906 individuals following hospital discharge (VTE rate was lower among patients on thromboprophylaxis). The rate of major bleeding was 1.7%. Among 1877 individuals who did not use postdischarge thromboprophylaxis, nine VTE events were ported (0.48%) and the median time to event was 8 days . 19 Ongoing larger studies such as CORONA-VTE, CISCO-19, and CORE-19 will provide more insight to this post-acute COVID-19 complication. 24, 42 Townsend et al., 43 should be considered for extended prophylaxis (up to 45 days). 27, 29 Standard risk factors such as active cancer, immobility, age, high BMI (body mass index), recent trauma, thrombophilia, surgery, and personal or familial history of VTE should be taken into account. The severity of COVID-19 disease is also included in risk assessment, and some authors also include elevated D-dimer levels (>2 times the upper limit of normal). 47, 48 Low-molecular-weight heparin and direct oral anticoagulants are generally preferred over VKAs due to the lack of need to monitor therapeutic levels. 29 Potential drug-drug interactions should also be considered. Autoimmune thrombocytopenic purpura (ITP), although rarely, has been recognized as a late manifestation of COVID-19. Potential mechanisms underlying SARS-CoV-2-mediated immune thrombocytopenia include immune system dysregulation, molecular mimicry, epitope spreading, and susceptibility mutations in SOCS 1 (Figure 1 ). Delayed-onset ITP has been reported in the post-acute phase, between 3 and 4 weeks after COVID-19 symptom onset. 50 lymphocytes at days 10-12 and less than 5% at days 17-19 seem to have the worst prognosis. 60 Lymphocytes express the ACE-2 receptor, enabling SARS-CoV-2 to bind directly and, consequently, leading to their lysis. 61 The cytokine storm is characterized by extremely high levels of interleukins (mainly IL-6, IL-2, IL-7, granulocyte colonystimulating factor, interferon-γ inducible protein 10, MCP-1, and MIP1-a) and tumor necrosis factor (TNF)-alpha, which may also induce lymphocyte apoptosis. [62] [63] [64] Persistent lymphocytopenia may be evident even at 5 weeks from disease onset, especially in patients with severe acute COVID-19 disease. 65 Neutropenia is a complication in many viral illnesses, but it is uncommon during the course of COVID-19. Neutropenia following COVID-19 infection has been associated with bone marrow suppression secondary to inflammatory response. It may resolve by itself following a wait-and-watch approach, especially in young healthy patients. 67 symptoms. 69 Therapeutic agents used at the acute phase of COVID-19 such as tocilizumab have been associated with prolonged neutropenia, even after the resolution of acute symptoms. 70 Thrombocytopenia is a common complication of viral infections. shown that thrombocytopenia is strongly associated with the severity of the disease. 71 Chen et al. 51 reported in a cohort of 271 hospitalized COVID-19 patients that 11.8% developed delayed-phase thrombocytopenia. More prone were elderly patients or patients with lymphopenia on admission. In this study, delayed thrombocytopenia had a significant negative correlation with the proportion of B cells. Bone marrow aspiration performed in three patients revealed impaired growth of megakaryocytes. Thirty percent of the subjects had still iron deficiency and 9% had anemia classified as inflammation anemia. These patients had increased inflammation biomarkers such as IL-6 and CRP. Hyperferritinemia remained present in 38% of the enrolled subjects and was more common in patients with severe or critical disease. The mRNA expression of peripheral blood mononuclear cells was investigated, which showed that there is an association between the increased ferritin levels and the cytokine mRNA expression. Furthermore, persisting hyperferritinemia correlated with severe lung disease and impaired performance status. 73 In conclusion, COVID-19 is a multisystemic disease with significant COVID-19: towards controlling of a pandemic Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia Potential effects of coronaviruses on the cardiovascular system: areview Follow-up studies in COVID-19 recovered patients-is it mandatory? A novel coronavirus from patients with pneumonia in China Epidemiology and organ specific sequelae of post-acute COVID19: a narrative review Cardiovascular considerations for patients, health care workers, and health systems during the coronavirus disease 2019 (COVID-19) pandemic COVID-19 and the liver: little cause for concern COVID-19: consider cytokine storm syndromes and immunosuppression Understanding the long-term health effects of COVID-19 Registry of arterial and venous thromboembolic complications in patients with COVID-19 Anticoagulation, bleeding, mortality, and pathology in hospitalized patients with COVID-19 COVID-19 and major organ thromboembolism: manifestations in neurovascular and cardiovascular systems Thromboembolic complications of COVID-19: the combined effect of a pro-coagulant pattern and an endothelial thrombo-inflammatory syndrome SARS-CoV-2 and coagulation disorders in different organs Long-COVID and post-COVID health complications: an up-to-date review on clinical conditions and their possible molecular mechanisms Incidence, risk factors, clinical characteristics and outcomes of deep venous thrombosis in patients with COVID-19 attending the emergency department: results of the UMC-19-S8 Postdischarge thrombosis and hemorrhage in patients with COVID-19 Postdischarge venous thromboembolism following hospital admission with COVID-19 Venous thromboembolism in patients discharged after COVID-19 hospitalization Incidence of thrombotic outcomes for patients hospitalized and discharged after COVID-19 infection 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study Postdischarge thromboembolic outcomes and mortality of hospitalized patients with COVID-19: the CORE-19 registry Scientific and standardization committee communication: clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19 COVID-19 and its implications for thrombosis and anticoagulation Recent randomized trials of antithrombotic therapy for patients with COVID-19: JACC state-of-the-art review Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forum ISTH interim guidance on recognition and management of coagulopathy in COVID-19 COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review Endothelial cell infection and endotheliitis in COVID-19 Severe COVID-19 infection associated with endothelial activation Evaluation of coagulation function by rotation thromboelastometry in critically ill patients with severe COVID-19 pneumonia Personalizing antithrombotic therapy in COVID-19: role of Thromboelastography and Thromboelastometry Coronavirus and cardiovascular disease, myocardial injury, and arrhythmia: JACC focus seminar Targeting raised von Willebrand factor levels and macrophage activation in severe COVID-19: consider low volume plasma exchange and low dose steroid The implications of COVID-19 infection on the endothelium: a metabolic vascular perspective Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19 Persistent endotheliopathy in the pathogenesis of long COVID syndrome Sars-CoV-2 virus infection may interfere CD34+ hematopoietic stem cells and megakaryocyte-Erythroid progenitors differentiation contributing to platelet defection towards insurgence of thrombocytopenia and thrombophilia Post-acute COVID-19 syndrome The Chief Scientist Office cardiovascular and pulmonary imaging in SARS coronavirus disease-19 (CISCO-19) study Prolonged elevation of D-dimer levels in convalescent COVID-19 patients is independent of the acute phase response Delayed catastrophic thrombotic events in young and asymptomatic post COVID-19 patients an RNAi therapeutic, for hereditary transthyretin amyloidosis Heparin in COVID-19 patients is associated with reduced in-hospital mortality: the multicenter Italian CORIST study Broadening the categories of patients eligible for extended venous thromboembolism treatment Modified IMPROVE VTE risk score and elevated D-dimer identify a high venous thromboembolism risk in acutely ill medical population for extended thromboprophylaxis Extended prophylaxis for venous thromboembolism after hospitalization for medical illness: a trial sequential and cumulative meta-analysis Clinical characteristics, management and outcome of COVID-19-associated immune thrombocytopenia: a French multicentre series Delayed-phase thrombocytopenia in patients with coronavirus disease 2019 (COVID-19) Immune thrombocytopenia secondary to COVID-19: a systematic review Hematologic autoimmune disorders in the course of COVID-19: a systematic review of reported cases Hematological findings and complications of COVID-19 Emerging evidence of a COVID-19 thrombotic syndrome has treatment implications Sustained prothrombotic changes in COVID-19 patients 4 months after hospital discharge Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 (COVID-19) in Wuhan, China: a retrospective study Dysregulation of immune response in patients with COVID-19 in Wuhan, China Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa High producer haplotype (CAG) of -863C/a, À308G/a and -238G/a polymorphisms in the promoter region of TNF-alpha gene associate with enhanced apoptosis of lymphocytes in HIV-1 subtype C infected individuals from North India IL-19 induces production of IL-6 and TNF-alpha and results in cell apoptosis through TNF-alpha Increased TNF-alpha-induced apoptosis in lymphocytes from aged humans: changes in TNF-alpha receptor expression and activation of caspases Dynamic changes in peripheral blood lymphocyte subsets in adult patients with COVID-19 A longitudinal follow-up of COVID-19 patients in the convalescent phase showed recovery in radiological results, the dynamics of lymphocytes, and a decrease in the level of IgG antibody: a single-Centre, observational study Delayed, transient and selfresolving neutropenia following COVID-19 pneumonia Post-COVID-19 severe neutropenia Agranulocytosis following COVID-19 recovery Thrombotic events following tocilizumab therapy in critically ill COVID-19 patients: a facade for prognostic markers Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a meta-analysis Cardiopulmonary recovery after COVID-19: an observational prospective multicentre trial Persisting alterations of iron homeostasis in COVID-19 are associated with non-resolving lung pathologies and poor patients' performance: a prospective observational cohort study Late-onset hematological complications post COVID-19: An emerging medical problem for the hematologist The authors declare that they have no conflict of interest. Data sharing is not applicable to this article as no new data were created or analyzed in this study.